Ironwood Reports FDA Approval Of New Indication For LINZESS (linaclotide) For Treatment O Functional Constipation In Pediatric Patients Ages 6-17 Years-Old
Portfolio Pulse from Benzinga Newsdesk
Ironwood Pharmaceuticals has received FDA approval for LINZESS (linaclotide) to treat functional constipation in pediatric patients aged 6-17 years. The approval was based on a successful Phase III study.
June 12, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie is not directly mentioned in the article, but it is a partner of Ironwood Pharmaceuticals in the development and commercialization of LINZESS.
Although AbbVie is not directly mentioned in the article, it is a partner of Ironwood Pharmaceuticals in the development and commercialization of LINZESS. The FDA approval for pediatric constipation treatment may have a positive impact on AbbVie's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Ironwood Pharmaceuticals' LINZESS receives FDA approval for treating functional constipation in pediatric patients aged 6-17 years.
The FDA approval of LINZESS for pediatric patients aged 6-17 years expands the market for the drug, which is likely to have a positive impact on Ironwood Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100